<p>X4 Pharmaceuticals（納斯達克代碼：XFOR - 獲取免費報告）在週三發佈給投資者的報告中，被 Zacks Research 的股票研究人員從 “強力買入” 評級下調至 “持有” 評級，Zacks.com 報道。</p>
<p>其他一些研究公司也對 XFOR 發表了評論。Stifel Nicolaus 在 11 月 5 日的研究報告中對 X4 Pharmaceuticals 設定了 7.50 美元的目標價。華爾街 Zen 在 11 月 22 日的研究報告中將 X4 Pharmaceuticals 的股票評級從 “賣出” 上調至 “持有”。HC Wainwright 在 8 月 13 日的研究報告中對 X4 Pharmaceuticals 的股票設定了 3.50 美元的目標價，並給予該公司 “買入” 評級。最後，Weiss Ratings 在週一的報告中重新發布了對 X4 Pharmaceuticals 的 “賣出（d-）” 評級。三位分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 “持有”，共識目標價為 33.67 美元。</p>
<p>獲取 <strong>X4 Pharmaceuticals</strong> 的提醒：</p>
<p><strong>查看我們關於 X4 Pharmaceuticals 的最新研究報告</strong></p>
<h2>X4 Pharmaceuticals 股價上漲 1.1%</h2>
<p>XFOR 的股票在週三以 3.68 美元開盤。該公司的流動比率為 5.65，速動比率為 5.48，債務與股本比率為 1.23。該股票的市值為 3.2178 億美元，市盈率為-0.36，貝塔值為 0.51。X4 Pharmaceuticals 的 1 年最低價為 1.35 美元，1 年最高價為 26.83 美元。該股票的 50 日簡單移動平均價為 3.52 美元，200 日簡單移動平均價為 2.98 美元。</p>
<p>X4 Pharmaceuticals（納斯達克代碼：XFOR - 獲取免費報告）最後一次公佈財報是在 11 月 5 日。該公司報告的每股收益（EPS）為（0.69 美元），超出分析師的共識預期（0.79 美元）0.10 美元。該業務在該季度的收入為 177 萬美元，而分析師的預期為 205 萬美元。X4 Pharmaceuticals 的淨利潤率為-279.86%，股本回報率為-343.67%。平均而言，賣方分析師預測 X4 Pharmaceuticals 在當前財年將發佈-0.68 的每股收益。</p>
<h2>內部活動</h2>
<p>在相關消息中，董事長 Adam R. Craig 在 10 月 23 日的交易中購買了 86,206 股該公司的股票。股票的平均購買成本為每股 2.90 美元，總價值為 249,997.40 美元。購買完成後，董事長直接持有該公司 376,087 股股票，價值約為 1,090,652.30 美元。這筆交易代表了他們持股比例的 29.74% 的增長。該購買在向證券交易委員會的備案中披露，相關信息可在 SEC 網站上查閲。2.37% 的股票由公司內部人士持有。</p>
<h2>對 X4 Pharmaceuticals 的對沖基金看法</h2>
<p>幾家機構投資者最近調整了對該公司的持股。查爾斯·施瓦布投資管理公司在第一季度將其在 X4 Pharmaceuticals 的持股增加了 9.9%。查爾斯·施瓦布投資管理公司目前擁有 481,528 股該公司的股票，價值 114,000 美元，此前在上個季度又購買了 43,320 股。Pale Fire Capital SE 在第一季度將其在 X4 Pharmaceuticals 的持股增加了 45.2%。Pale Fire Capital SE 目前擁有 2,035,362 股該公司的股票，價值 481,000 美元，此前在上個季度又購買了 633,398 股。Kingdon Capital Management L.L.C.在第一季度將其在 X4 Pharmaceuticals 的持股增加了 41.8%。Kingdon Capital Management L.L.C.目前擁有 7,000,000 股該公司的股票，價值 1,655,000 美元，此前在上個季度又購買了 2,063,000 股。Acorn Capital Advisors LLC 在第三季度將其在 X4 Pharmaceuticals 的持股增加了 77.8%。Acorn Capital Advisors LLC 目前擁有 273,349 股該公司的股票，價值 935,000 美元，此前在上個季度又購買了 119,619 股。最後，Boothbay Fund Management LLC 在第三季度購買了 X4 Pharmaceuticals 的新頭寸，價值 1,176,000 美元。機構投資者持有該公司 72.03% 的股票。</p>
<h2>X4 Pharmaceuticals 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>X4 Pharmaceuticals, Inc 是一家處於後期臨牀階段的生物製藥公司，專注於稀有疾病的創新治療藥物的研究、開發和商業化。其主要產品候選藥物是 mavorixafor，一種小分子化合物，抑制趨化因子受體 C-X-C 趨化因子受體 4（CXCR4），目前正在進行針對疣、低丙種球蛋白血癥、感染和骨髓滯留綜合症的 III 期臨牀試驗；以及針對先天性、特發性或週期性中性粒細胞減少症的 II 期臨牀試驗。</p>
<h2>推薦閲讀</h2>
<ul>
<li>我們更看好的五隻股票超過 X4 Pharmaceuticals</li>
<li>揭示 VWAP 的力量：交易者的關鍵指標</li>
<li>MarketBeat 週迴顧 – 11/24 - 11/28</li>
<li>多元化可以平滑收益並降低投資組合風險</li>
<li>持續發力：Applied Digital 的首個 AI 數據中心上線</li>
<li>股票拆分意味着什麼？</li>
<li>Alphabet：最有可能主導 2026 年的 AI 領導者</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEZPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEZPUg"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 X4 Pharmaceuticals 嗎？</h2>
<p>在你考慮 X4 Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 X4 Pharmaceuticals 並不在名單上。</p>
<p>雖然 X4 Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

XFOR

<p>Zacks Research 將 X4 Pharmaceuticals（NASDAQ:XFOR）的評級從 “強力買入” 下調至 “持有”。其他分析師的評級各不相同，平均評級為 “持有”，共識目標價為 33.67 美元。該股票週三開盤價為 3.68 美元。X4 Pharmaceuticals 報告第三季度每股收益為（0.69 美元），超出預期 0.10 美元。機構投資者持有該股票 72.03%</p>

<p>X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) was downgraded by equities researchers at Zacks Research from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a note issued to investors on Wednesday,Zacks.com reports.</p>
<div class="lb-trans"><p>X4 Pharmaceuticals（納斯達克代碼：XFOR - 獲取免費報告）在週三發佈給投資者的報告中，被 Zacks Research 的股票研究人員從 “強力買入” 評級下調至 “持有” 評級，Zacks.com 報道。</p>
</div><p>A number of other research firms have also commented on XFOR. Stifel Nicolaus set a $7.50 price objective on X4 Pharmaceuticals in a research note on Wednesday, November 5th. Wall Street Zen upgraded shares of X4 Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 22nd. HC Wainwright set a $3.50 price target on shares of X4 Pharmaceuticals and gave the company a &#34;buy&#34; rating in a research note on Wednesday, August 13th. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of X4 Pharmaceuticals in a report on Monday. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Hold&#34; and a consensus price target of $33.67.</p>
<div class="lb-trans"><p>其他一些研究公司也對 XFOR 發表了評論。Stifel Nicolaus 在 11 月 5 日的研究報告中對 X4 Pharmaceuticals 設定了 7.50 美元的目標價。華爾街 Zen 在 11 月 22 日的研究報告中將 X4 Pharmaceuticals 的股票評級從 “賣出” 上調至 “持有”。HC Wainwright 在 8 月 13 日的研究報告中對 X4 Pharmaceuticals 的股票設定了 3.50 美元的目標價，並給予該公司 “買入” 評級。最後，Weiss Ratings 在週一的報告中重新發布了對 X4 Pharmaceuticals 的 “賣出（d-）” 評級。三位分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，該公司的平均評級為 “持有”，共識目標價為 33.67 美元。</p>
</div><p>Get <strong>X4 Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>X4 Pharmaceuticals</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Research Report on X4 Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 X4 Pharmaceuticals 的最新研究報告</strong></p>
</div><h2>X4 Pharmaceuticals Trading Up 1.1%</h2>
<div class="lb-trans"><h2>X4 Pharmaceuticals 股價上漲 1.1%</h2>
</div><p>Shares of XFOR opened at $3.68 on Wednesday. The company has a current ratio of 5.65, a quick ratio of 5.48 and a debt-to-equity ratio of 1.23. The stock has a market cap of $321.78 million, a PE ratio of -0.36 and a beta of 0.51. X4 Pharmaceuticals has a 1 year low of $1.35 and a 1 year high of $26.83. The stock has a 50 day simple moving average of $3.52 and a 200-day simple moving average of $2.98.</p>
<div class="lb-trans"><p>XFOR 的股票在週三以 3.68 美元開盤。該公司的流動比率為 5.65，速動比率為 5.48，債務與股本比率為 1.23。該股票的市值為 3.2178 億美元，市盈率為-0.36，貝塔值為 0.51。X4 Pharmaceuticals 的 1 年最低價為 1.35 美元，1 年最高價為 26.83 美元。該股票的 50 日簡單移動平均價為 3.52 美元，200 日簡單移動平均價為 2.98 美元。</p>
</div><p>X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.10. The business had revenue of $1.77 million during the quarter, compared to analysts' expectations of $2.05 million. X4 Pharmaceuticals had a negative net margin of 279.86% and a negative return on equity of 343.67%. On average, sell-side analysts predict that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>X4 Pharmaceuticals（納斯達克代碼：XFOR - 獲取免費報告）最後一次公佈財報是在 11 月 5 日。該公司報告的每股收益（EPS）為（0.69 美元），超出分析師的共識預期（0.79 美元）0.10 美元。該業務在該季度的收入為 177 萬美元，而分析師的預期為 205 萬美元。X4 Pharmaceuticals 的淨利潤率為-279.86%，股本回報率為-343.67%。平均而言，賣方分析師預測 X4 Pharmaceuticals 在當前財年將發佈-0.68 的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In related news, Chairman Adam R. Craig acquired 86,206 shares of the firm's stock in a transaction that occurred on Thursday, October 23rd. The stock was acquired at an average cost of $2.90 per share, with a total value of $249,997.40. Following the completion of the purchase, the chairman directly owned 376,087 shares in the company, valued at approximately $1,090,652.30. This trade represents a 29.74% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website. 2.37% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事長 Adam R. Craig 在 10 月 23 日的交易中購買了 86,206 股該公司的股票。股票的平均購買成本為每股 2.90 美元，總價值為 249,997.40 美元。購買完成後，董事長直接持有該公司 376,087 股股票，價值約為 1,090,652.30 美元。這筆交易代表了他們持股比例的 29.74% 的增長。該購買在向證券交易委員會的備案中披露，相關信息可在 SEC 網站上查閲。2.37% 的股票由公司內部人士持有。</p>
</div><h2>Hedge Funds Weigh In On X4 Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 X4 Pharmaceuticals 的對沖基金看法</h2>
</div><p>Several institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its holdings in X4 Pharmaceuticals by 9.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 481,528 shares of the company's stock worth $114,000 after acquiring an additional 43,320 shares in the last quarter. Pale Fire Capital SE raised its stake in shares of X4 Pharmaceuticals by 45.2% during the 1st quarter. Pale Fire Capital SE now owns 2,035,362 shares of the company's stock worth $481,000 after purchasing an additional 633,398 shares in the last quarter. Kingdon Capital Management L.L.C. boosted its holdings in shares of X4 Pharmaceuticals by 41.8% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 7,000,000 shares of the company's stock valued at $1,655,000 after buying an additional 2,063,000 shares during the last quarter. Acorn Capital Advisors LLC boosted its holdings in shares of X4 Pharmaceuticals by 77.8% in the 3rd quarter. Acorn Capital Advisors LLC now owns 273,349 shares of the company's stock valued at $935,000 after buying an additional 119,619 shares during the last quarter. Finally, Boothbay Fund Management LLC bought a new position in shares of X4 Pharmaceuticals in the third quarter valued at $1,176,000. Institutional investors own 72.03% of the company's stock.</p>
<div class="lb-trans"><p>幾家機構投資者最近調整了對該公司的持股。查爾斯·施瓦布投資管理公司在第一季度將其在 X4 Pharmaceuticals 的持股增加了 9.9%。查爾斯·施瓦布投資管理公司目前擁有 481,528 股該公司的股票，價值 114,000 美元，此前在上個季度又購買了 43,320 股。Pale Fire Capital SE 在第一季度將其在 X4 Pharmaceuticals 的持股增加了 45.2%。Pale Fire Capital SE 目前擁有 2,035,362 股該公司的股票，價值 481,000 美元，此前在上個季度又購買了 633,398 股。Kingdon Capital Management L.L.C.在第一季度將其在 X4 Pharmaceuticals 的持股增加了 41.8%。Kingdon Capital Management L.L.C.目前擁有 7,000,000 股該公司的股票，價值 1,655,000 美元，此前在上個季度又購買了 2,063,000 股。Acorn Capital Advisors LLC 在第三季度將其在 X4 Pharmaceuticals 的持股增加了 77.8%。Acorn Capital Advisors LLC 目前擁有 273,349 股該公司的股票，價值 935,000 美元，此前在上個季度又購買了 119,619 股。最後，Boothbay Fund Management LLC 在第三季度購買了 X4 Pharmaceuticals 的新頭寸，價值 1,176,000 美元。機構投資者持有該公司 72.03% 的股票。</p>
</div><h2>X4 Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>X4 Pharmaceuticals 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.</p>
<div class="lb-trans"><p>X4 Pharmaceuticals, Inc 是一家處於後期臨牀階段的生物製藥公司，專注於稀有疾病的創新治療藥物的研究、開發和商業化。其主要產品候選藥物是 mavorixafor，一種小分子化合物，抑制趨化因子受體 C-X-C 趨化因子受體 4（CXCR4），目前正在進行針對疣、低丙種球蛋白血癥、感染和骨髓滯留綜合症的 III 期臨牀試驗；以及針對先天性、特發性或週期性中性粒細胞減少症的 II 期臨牀試驗。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推薦閲讀</h2>
</div><ul>
<li>Five stocks we like better than X4 Pharmaceuticals</li>
<li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li>
<li>MarketBeat Week in Review – 11/24 - 11/28</li>
<li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li>
<li>Power On: Applied Digital’s First AI Data Center Goes Live</li>
<li>What Does a Stock Split Mean?</li>
<li>Alphabet: The AI Leader Best Positioned to Dominate 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 X4 Pharmaceuticals</li>
<li>揭示 VWAP 的力量：交易者的關鍵指標</li>
<li>MarketBeat 週迴顧 – 11/24 - 11/28</li>
<li>多元化可以平滑收益並降低投資組合風險</li>
<li>持續發力：Applied Digital 的首個 AI 數據中心上線</li>
<li>股票拆分意味着什麼？</li>
<li>Alphabet：最有可能主導 2026 年的 AI 領導者</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEZPUg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=XFOR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in X4 Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 X4 Pharmaceuticals 嗎？</h2>
</div><p>Before you consider X4 Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 X4 Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and X4 Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 X4 Pharmaceuticals 並不在名單上。</p>
</div><p>While X4 Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 X4 Pharmaceuticals 目前在分析師中被評為持有評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

X4 Pharmaceuticals（納斯達克股票代碼：XFOR）的股票評級被 Zacks Research 下調